Exactitude Consultancy Press Release: Antinuclear Antibody Test Market

Rising investments in the development of diagnostic platforms for autoimmune conditions such as rheumatoid arthritis and others are expected to aid market growth. 

Market expansion is anticipated to be aided by rising investments in the creation of diagnostic platforms for autoimmune conditions like rheumatoid arthritis and others. For instance, Prantae Solutions will receive funding in 2021 through the India-Russia Joint Technology Assessment and Accelerated Commercialization Programme to create a platform for multiplex immunofluorescence analysis, a method used to quickly diagnose RA using disposable cartridges. As a result, this factor spurs Market expansion.

The growth of the global antinuclear antibody test market is hampered by diagnostic mistakes, product approval issues, and a lack of skilled labour.

The strict U.S. FDA regulations for product approval, a shortage of skilled labour, and diagnostic mistakes are the main factors likely to impede the growth of the anti-nuclear Antibody testing market globally. For instance, according to the American College of Rheumatology, anti-nuclear antibody tests may yield false positive results in healthy individuals who are free of any medical conditions or in individuals who are taking medications like isoniazid and procainamide. Although the anti-nuclear antibody test is a highly sensitive diagnostic tool, its lack of specificity may limit market expansion.

Explore 188 market data Tables spread through nearly 125 Pages and in-depth analysis on “Antinuclear Antibody Test Market By product (Reagents & Assay Kits, Systems, Software & Services), technique (ELISA, Immunofluorescence Assay, Multiplex Assay), disease (Rheumatoid Arthritis, Systemic Lupus Erythematosus, Sjogren’s Syndrome, Scleroderma, Others), end user (Hospitals, Clinical Laboratories, Physician Office Laboratories, Others) And Region, Global Trends And Forecast From 2022 To 2029” with Table of Contents.

The expanding healthcare infrastructure and research initiatives will create opportunities for antinuclear antibody test market.

The Antinuclear Antibody (ANA) test market offers numerous chances for expansion and improvement. The demand for ANA testing is predicted to increase as autoimmune diseases become more common. Technology advancements like automated systems and multiplex assays offer increased accuracy and effectiveness. The market’s potential growth is also influenced by rising awareness, expanding healthcare infrastructure, and research initiatives.

The COVID-19 epidemic had a positive influence on the antinuclear antibody test market.

There were lockdowns and quarantines because of the coronavirus epidemic in China. Numerous companies have suffered losses as a result of travel restrictions. The unemployment rate rose as more fatalities were reported. Additionally, because of the unanticipated increase in patients and the severe shortage of hospital resources, such as oxygen cylinders, beds, and staff, the financial situation has gotten worse. The circumstances brought on by the coronavirus had a favourable effect on the market for antinuclear antibody tests. To find any antibodies in the blood, antibody screenings will be carried out. These are used to combat diseases like COVID-19. Serologic techniques have also been created as a response to the COVID-19 pandemic. The market for antinuclear antibody tests is therefore crucial for COVID-19.

Assay kites & reagents segment held the largest market share of antinuclear antibody test market.

The largest portion of the global ANA testing market is accounted for by the Assay Kits & Reagents segment. It might be related to the rise in reagent rental contracts. Additionally, the growth is linked to elements like a typical rise in autoimmune diseases, high reagent and assay kit acquisition, better efficiency changes, results that are valuable and cost-saving measures.

The antinuclear antibody test market key players include Erba Diagnostics, Bio-Rad Laboratories Inc., Trinity Biotech Plc., Thermo Fisher Scientific, Antibodies Incorporated, EUROIMMUN AG, Immuno Concepts NA Ltd., Inova Diagnostics Inc., ZEUS Scientific Inc., Alere Inc., and others.

Recent Developments:

• 25 February 2021: Antibodies Incorporated announced that Immunochemistry Technologies (ICT) has joined our growing family of Janel Life Sciences companies that now includes Antibodies Incorporated, PhosphoSolutions, AvesLabs, and Immunochemistry Technologies (ICT).
• 09 May 2023: Pfizer and Thermo Fisher Scientific Inc. (NYSE: TMO) announced they have entered into a collaboration agreement to help increase local access to next-generation sequencing (NGS)-based testing for lung and breast cancer patients.

North America dominates the antinuclear antibody test market.

North America is the largest market for anti-nuclear antibody testing, followed by Europe, with Asia Pacific experiencing the fastest growth. However, due to a lack of knowledge about medical advancements and treatments for diseases linked to anti-nuclear antibodies, it is anticipated that the Middle East and Africa will only experience modest market growth. The dominance of the North American anti-nuclear antibody testing market can be attributed to a number of factors, including the ageing of the population and the rise in autoimmune diseases like rheumatoid arthritis and SLE. The American Autoimmune Related Disease Association (AARDA), for instance, has published a list of more than 100 different autoimmune disorders that are prevalent in the United States.

Key Market Segments: Antinuclear Antibody Test Market

by Product, 2020-2029, (USD Billion, Thousand Units)

• Reagents & Assay Kits
• Systems
• Software & Services

by Technique, 2020-2029, (USD Billion, Thousand Units)

• ELISA
• Immunofluorescence Assay
• Multiplex Assay

by Disease, 2020-2029, (USD Billion, Thousand Units)

• Rheumatoid Arthritis
• Systemic Lupus Erythematosus
• Sjogren’s Syndrome
• Scleroderma
• Others

by End User, 2020-2029, (USD Billion, Thousand Units)

• Hospitals
• Clinical Laboratories
• Physician Office Laboratories
• Others

by Region, 2020-2029, (USD Billion, Thousand Units)

• North America
• Asia Pacific
• Europe
• South America
• Middle East and Africa

Important Countries in All Regions Are Covered.

The post The Growing Investments by Market Players are Driving Growth in the Market for Antinuclear Antibody Test appeared first on Exactitude Consultancy.